INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Other Events

INCYTE CORPORATION (NASDAQ:INCY) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On April6, 2018,Incyte Corporation (“Incyte”) and Merck announced that an external Data Monitoring Committee (“eDMC”) review of the ECHO-301 Phase III clinical trial results evaluating epacadostat,Incyte’s investigational IDO1 enzyme inhibitor, in combination with pembrolizumab in patients with unresectable or metastatic melanoma determined that the ECHO-301 trial did not meet the primary endpoint of improving progression-free survival compared to pembrolizumab monotherapy and that the second primary endpoint of overall survival is not expected to reach statistical significance and, based on these results and at the recommendation of the eDMC, the ECHO-301 trial will be stopped.


About INCYTE CORPORATION (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company’s pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company’s second oral JAK1 and JAK2 inhibitor is baricitinib.

An ad to help with our costs